NCT05422482View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Mucopolysaccharidosis IIHunter Syndrome
Interventions
BIOLOGICAL

GC1123

ICV-administered Hunterase, Idursulfase-ß

Trial Locations (3)

50612

Pusan National University Yangsan Hospital, Pusan

03080

Seoul National University, Seoul

06351

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

GC Biopharma Corp
All Listed Sponsors
lead

GC Biopharma Corp

INDUSTRY